Truist raised the firm’s price target on Autolus Therapeutics (AUTL)to $10 from $9 and keeps a Buy rating on the shares. The firm anticipates a “transformative year” for the company as it advances towards commercializing Obe-cel in its first indication and defines Obe-cel’s profile in the autoimmune arena, the analyst tells investors in a research note. Despite the recent platform validation by BioNTech (BNTX), investors are likely missing the attractiveness of Obe-cel in adult Acute Lymphoblastic Leukemia, or ALL, the firm adds, modeling Autolus to be the “dominant CAR-T contender”.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AUTL:
- Autolus Therapeutics Announces Annual Results and CDO Resignation
- Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
- Autolus Therapeutics says ‘well capitalized’ for pipeline development plans
- Autolus Therapeutics reports 2023 EPS ($1.20), consensus ($1.01)
- Autolus Therapeutics receives MHRA certification for Nucleus site
